The Global Prevalence of Parkinson’s Disease: Who is Affected?

Last updated on:

February 20, 2026

Parkinson’s disease is often pictured as something that happens to the very elderly – a trembling hand, a shuffling gait, a condition of old age. But that picture is incomplete, and increasingly, the data tells a more complex story. Today, Parkinson’s disease is recognized as a rapidly growing global health crisis, affecting millions across age groups, geographies, and both sexes – and it is doing so faster than any other neurological disorder on the planet.

Who gets Parkinson’s disease?
The primary demographic: middle-aged and older adults
Parkinson’s is not exclusively a disease of the elderly
Gender disparity in Parkinson’s disease
Why are men more affected?
The gender gap is not the whole story
Rapidly increasing global rates
What is driving the increase?
The burden in numbers
Why this matters beyond medicine

Who gets Parkinson’s disease?

Parkinson’s disease is caused by the progressive loss of dopamine-producing neurons in the brain. It affects movement, muscle control, and balance, and comes with a wide range of non-motor symptoms including cognitive changes, depression, and pain. But the question of who it affects is not as straightforward as many people assume. Age, sex, geography, and genetics all play a role – and the patterns are shifting.

The primary demographic: middle-aged and older adults

Age remains the single strongest risk factor for Parkinson’s disease. According to the Parkinson’s Foundation, the incidence of the disease increases steadily with age, particularly in those over 65. Research published in the Journal of Parkinson’s Disease reports that the condition affects roughly 3% of the population by age 65, rising to as many as 5% in individuals over 85. In the Western world, the average age at which symptoms first appear is the early-to-mid 60s.

This strong age association exists because the neurological changes underlying Parkinson’s – particularly the accumulation of abnormal protein clumps called alpha-synuclein – develop slowly over many years before symptoms become visible. By the time a diagnosis is made, significant neuronal loss has already occurred. Aging accelerates this process and reduces the brain’s capacity for repair.

Parkinson’s is not exclusively a disease of the elderly

Here is where the conventional picture breaks down. The World Health Organization (WHO) has noted that Parkinson’s disease is not limited to older populations, and cases in younger individuals are becoming an increasingly important concern. When the disease appears in someone under the age of 50, it is clinically referred to as Young-Onset Parkinson’s Disease (YOPD) – and it is more common than many people realize.

The Parkinson’s Foundation estimates that about 4% of the over one million people living with Parkinson’s in the United States were diagnosed before age 50. The American Parkinson Disease Association (APDA) puts this figure higher – estimating that 10-20% of those diagnosed are under 50. Research using the Global Burden of Disease (GBD) 2021 database confirms that between 5% and 10% of all Parkinson’s cases globally have their onset between ages 21 and 50.

In 2021 alone, the GBD study recorded an estimated 81,047 new cases of early-onset Parkinson’s and over 483,000 people living with the condition globally in the under-50 age group. These numbers represent a significant and growing portion of the overall disease burden. Researchers attribute part of the rise in early-onset cases to improved diagnostic awareness, better neuroimaging, and genetic testing – but population growth and genuine epidemiological shifts are also contributing factors.

For younger people diagnosed with Parkinson’s, the experience is distinctly different. Johns Hopkins Medicine notes that while symptoms are largely similar to late-onset cases, younger patients are often in the middle of their careers, raising children, and managing financial obligations – making the diagnosis particularly disruptive. On a medical level, research published in PMC shows that YOPD tends to progress more slowly, with fewer cognitive complications early on, but carries a higher risk of medication-related movement side effects such as dyskinesias over time.

Gender disparity in Parkinson’s disease

One of the most consistent findings across global Parkinson’s research is that the disease affects men more frequently than women. The Parkinson’s Foundation reports that men are 1.5 times more likely to develop the disease than women. A review published in the Journal of Parkinson’s Disease found that the risk of developing PD is approximately twice as high in men as in women. A 2024 systematic review and meta-analysis in The Lancet eClinicalMedicine covering data from 1980 to 2023 confirmed a statistically significant higher prevalence in males (1.54 per 1,000) compared to females (1.49 per 1,000).

Why are men more affected?

The reasons behind this gender gap are not fully understood, and researchers believe it is likely due to a combination of biological, environmental, and social factors rather than any single cause.

One of the most studied explanations involves the hormone estrogen. Research highlighted by the APDA indicates that estrogen may offer a degree of neuroprotection – laboratory studies have shown it can help prevent the death of dopamine-producing brain cells, reduce cellular damage, and inhibit the clumping of alpha-synuclein protein, which is a hallmark of Parkinson’s. This protective effect may help explain why pre-menopausal women have lower rates of the disease. However, the relationship between estrogen and Parkinson’s is complex and not yet fully resolved.

Occupational and environmental exposure is another key factor. Research from the IRCCS Mondino Foundation points out that men have historically been more likely to work in agriculture, metallurgy, and industries with exposure to pesticides and neurotoxic solvents – all of which have been associated with an elevated risk of Parkinson’s. A systematic review published in PMC also found that associations between pesticide exposure and Parkinson’s risk have so far been documented predominantly in men, not women.

Additional proposed explanations from a meta-analysis in the Journal of Neurology, Neurosurgery & Psychiatry include differences in exposure to head trauma, mitochondrial dysfunction patterns, and the possible X-linkage of certain genetic risk factors – all of which may tip the biological balance toward greater male vulnerability.

The gender gap is not the whole story

While men are diagnosed more often, the disease does not treat women more kindly once they have it. Research shows that women experience faster disease progression and a higher mortality rate compared to men. A narrative review in Neurology and Therapy found that women are more prone to disabling motor complications and non-motor fluctuations, while men face higher risks of cognitive decline and gait disorders. The Parkinson’s Foundation also notes that women with PD are more likely to attend medical appointments alone and are less likely to receive surgical treatments like deep brain stimulation – despite reporting greater improvements from it when they do.

This points to a significant gap in research and clinical care. Historically, Parkinson’s disease has been studied predominantly in older white men, which has led to delayed diagnoses for women, younger people, and people of diverse ethnic backgrounds.

Rapidly increasing global rates

Perhaps the most alarming aspect of Parkinson’s disease today is how quickly it is spreading worldwide. According to the WHO’s 2022 technical brief on Parkinson’s disease, the global prevalence of the condition has doubled over the past 25 years – with over 8.5 million people estimated to be living with it as of 2019. Disability and death attributable to Parkinson’s are now rising faster than for any other neurological disorder.

Longer-term data reinforces just how dramatic this growth has been. A population-based study published in BMJ Open using GBD 2021 data found that global Parkinson’s prevalence rose by 274% – from 3.15 million cases in 1990 to 11.77 million in 2021. A 2024 meta-analysis spanning 83 studies from 37 countries found that prevalence in the 2010-2023 period (3.81 per 1,000) was more than four times the prevalence recorded in the 1980s (0.90 per 1,000).

What is driving the increase?

The primary driver of rising Parkinson’s prevalence is the world’s aging population. As more people live longer, the pool of individuals at risk for age-related neurological conditions expands. Research published in Frontiers in Neurology notes that increased life expectancy directly translates to more people reaching the age at which Parkinson’s becomes likely.

But aging alone does not account for the full picture. The Lancet’s epidemiological review highlights that Parkinson’s prevalence has risen over and above what demographic change alone would predict – suggesting that environmental, lifestyle, and possibly genetic factors are also contributing. Researchers have pointed to increasing exposure to pesticides, industrial chemicals (such as trichloroethylene), and other neurotoxins as potential environmental contributors to rising case rates.

Improved diagnostic awareness and access to neurological care in more regions of the world also play a role – cases that may previously have gone undetected or undiagnosed are now being counted. However, this improved detection is not uniform. A systematic review in npj Parkinson’s Disease found that reported prevalence varies enormously across regions, from as low as 49 per 100,000 in Sub-Saharan Africa to over 1,000 per 100,000 in parts of Latin America and the Caribbean – differences that likely reflect both genuine variation and significant gaps in healthcare access and data quality in lower-income countries.

The burden in numbers

The human and economic cost of this growth is substantial. The WHO estimates that by 2019, Parkinson’s disease accounted for 5.8 million disability-adjusted life years – an 81% increase since 2000 – and caused approximately 329,000 deaths, representing a rise of over 100% in the same period. In the United States alone, the Parkinson’s Foundation reports that a 2022 study found nearly 90,000 new diagnoses each year – a 50% jump from earlier estimates – with the combined economic cost of the disease calculated at $82.2 billion in 2024.

Projections for the coming decades are similarly striking. The GBD-based forecasting model suggests that without major intervention, the global burden of Parkinson’s will continue on its steep upward trajectory, driven by population aging and growing exposure to risk factors in low- and middle-income countries.

Why this matters beyond medicine

The growing prevalence of Parkinson’s disease is not only a medical issue – it is a social, economic, and educational one. Educators and those working with individuals with disabilities need to understand that Parkinson’s now touches a broader and younger demographic than it once did. A condition that was once considered primarily a concern of the very old is now a reality for working-age adults, parents, and caregivers across the globe. Understanding who is affected – and why the numbers are climbing – is the first step toward building systems of care, support, and inclusion that are truly fit for purpose.

What do you think? Given that Parkinson’s disease is now increasingly affecting people under 50, how do you think workplaces and educational institutions should adapt to better support younger individuals living with the condition? And considering the significant gender differences in both the risk and experience of Parkinson’s disease, what does this tell us about the need for sex-specific research and personalized care in neurology?

References

PDF 📄

The Global Prevalence of Parkinson’s Disease: Who is Affected?

Table of Contents

Who gets Parkinson’s disease? 🔗

The primary demographic: middle-aged and older adults 🔗

Parkinson’s is not exclusively a disease of the elderly 🔗

Gender disparity in Parkinson’s disease 🔗

Why are men more affected? 🔗

The gender gap is not the whole story 🔗

Rapidly increasing global rates 🔗

What is driving the increase? 🔗

The burden in numbers 🔗

Why this matters beyond medicine 🔗